CALGARY, Alberta, --- February 21, 2008 – Dr. Matt Coffey, Chief Scientific Officer of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate as an invited speaker in a session entitled “Case Studies in Gene Therapies” at the Oncology Biologics Development Primer (OBDP) conference on Friday, February 29, 2008. The OBDP was developed by the International Society for Biological Therapy of Cancer (iSBTc) to explore and discuss best practices for worldwide biologics development. The conference runs from February 28-29, 2008 in Gaithersburg, MD.
For more information about the conference, please visit www.isbtc.org and click on “Oncology Biologics Development Primer.”
Saturday, February 23, 2008
Tuesday, February 19, 2008
Virus as Viable Drug
"Coincidence or phenomena? The reovirus is Mother Nature's own cancer-killer." Provocative headlines from PharmExec.com.
Read the full article here.
Read the full article here.
Saturday, February 9, 2008
Latest update on Kenny
Kenny, a patient in the San Antonio trials, checks in with some new information:
...this last time, I also had a PET scan (my first one). The results showed “no metabolic activity”, which “suggests” that there may not be any active cancer cells anywhere. Medically speaking, there seems to be little evidence that I have cancer any more...
Exciting indeed. I encourage everyone to keep Kenny in your prayers.
Read the full article here.
...this last time, I also had a PET scan (my first one). The results showed “no metabolic activity”, which “suggests” that there may not be any active cancer cells anywhere. Medically speaking, there seems to be little evidence that I have cancer any more...
Exciting indeed. I encourage everyone to keep Kenny in your prayers.
Read the full article here.
Wednesday, February 6, 2008
Oncolytics Biotech Inc. to Present at Bio CEO & Investor Conference
CALGARY, Alberta, --- February 6, 2008
Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate as an invited speaker as part of a panel discussion entitled “Breaking Down the Barriers to New Neuro-Oncology Drugs” at the 10th Annual Bio CEO & Investor Conference 2008 on Monday, February 11 at 9:30 a.m. (ET). The conference, which is expected to draw more than 1,000 biotechnology and life sciences investors, will be held at the Waldorf-Astoria Hotel in New York City on February 11-13, 2008.
Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate as an invited speaker as part of a panel discussion entitled “Breaking Down the Barriers to New Neuro-Oncology Drugs” at the 10th Annual Bio CEO & Investor Conference 2008 on Monday, February 11 at 9:30 a.m. (ET). The conference, which is expected to draw more than 1,000 biotechnology and life sciences investors, will be held at the Waldorf-Astoria Hotel in New York City on February 11-13, 2008.
Monday, February 4, 2008
Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy
CALGARY, Canada, February 4 /PRNewswire/
Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ('Oncolytics') reported today that Dr. Kevin Harrington and his research group at The Institute of Cancer Research, London, U.K. published the results of their work testing combination treatment schedules of reovirus and radiation in human and murine tumour cells in vitro and in vivo. The paper, entitled "Enhanced In vitro and In vivo Cytotoxicity of Combined Reovirus and Radiotherapy" appears online in the February 1, 2008 issue of Clinical Cancer Research.
The effect of different schedules of reovirus and radiotherapy on viral replication and cytotoxicity was tested in vitro and the combination was assessed in three tumour models in vivo. The results demonstrated that combining reovirus and radiotherapy significantly increased cancer cell killing both in vitro and in vivo, particularly in cell lines with moderate susceptibility to reovirus alone.
"Dr. Harrington's work demonstrates convincingly that REOLYSIN® works to enhance the effects of radiation therapy," said Dr. Matt Coffey, Chief Scientific Officer of Oncolytics. "The results of this preclinical research provided strong support for the combination REOLYSIN® and radiation clinical trials we are conducting in the U.K. To date, we have successfully completed enrolment in a Phase Ia/Ib combination REOLYSIN® and radiation trial and are currently enrolling patients in a Phase II trial using this combination".
From the abstract:
Results: Characterization of reovirus cytotoxicity in a panel of cell lines yielded a range of sensitivities. Combined reovirus and radiotherapy yielded statistically significantly increased cytotoxicity, particularly in cell lines with moderate susceptibility to reovirus alone. The enhanced cytotoxicity of the combination occurred independently of treatment sequence or schedule. Radiation did not affect viral replication and only reduced reoviral cytotoxicity after clinically irrelevant single doses (>50 Gy). Combination index analysis revealed synergy between radiation (3-10 Gy) and reovirus at multiplicities of infection between 0.001 and 1. Combination treatment significantly increased apoptosis in tumor cells relative to either single-agent treatment. In vivo studies using xenograft and syngeneic tumors showed enhanced activity of the combination relative to reovirus or radiation alone (P <>
View the complete abstract here.
Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ('Oncolytics') reported today that Dr. Kevin Harrington and his research group at The Institute of Cancer Research, London, U.K. published the results of their work testing combination treatment schedules of reovirus and radiation in human and murine tumour cells in vitro and in vivo. The paper, entitled "Enhanced In vitro and In vivo Cytotoxicity of Combined Reovirus and Radiotherapy" appears online in the February 1, 2008 issue of Clinical Cancer Research.
The effect of different schedules of reovirus and radiotherapy on viral replication and cytotoxicity was tested in vitro and the combination was assessed in three tumour models in vivo. The results demonstrated that combining reovirus and radiotherapy significantly increased cancer cell killing both in vitro and in vivo, particularly in cell lines with moderate susceptibility to reovirus alone.
"Dr. Harrington's work demonstrates convincingly that REOLYSIN® works to enhance the effects of radiation therapy," said Dr. Matt Coffey, Chief Scientific Officer of Oncolytics. "The results of this preclinical research provided strong support for the combination REOLYSIN® and radiation clinical trials we are conducting in the U.K. To date, we have successfully completed enrolment in a Phase Ia/Ib combination REOLYSIN® and radiation trial and are currently enrolling patients in a Phase II trial using this combination".
From the abstract:
Results: Characterization of reovirus cytotoxicity in a panel of cell lines yielded a range of sensitivities. Combined reovirus and radiotherapy yielded statistically significantly increased cytotoxicity, particularly in cell lines with moderate susceptibility to reovirus alone. The enhanced cytotoxicity of the combination occurred independently of treatment sequence or schedule. Radiation did not affect viral replication and only reduced reoviral cytotoxicity after clinically irrelevant single doses (>50 Gy). Combination index analysis revealed synergy between radiation (3-10 Gy) and reovirus at multiplicities of infection between 0.001 and 1. Combination treatment significantly increased apoptosis in tumor cells relative to either single-agent treatment. In vivo studies using xenograft and syngeneic tumors showed enhanced activity of the combination relative to reovirus or radiation alone (P <>
View the complete abstract here.
Subscribe to:
Posts (Atom)
